纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤。
Nivolumab plus ipilimumab in the treatment of advanced melanoma.
作者信息
Tsai Katy K, Daud Adil I
机构信息
Helen Diller Comprehensive Cancer Center, University of California, 1600 Divisadero St., Box 1770, San Francisco, CA, 94115, USA.
出版信息
J Hematol Oncol. 2015 Oct 31;8:123. doi: 10.1186/s13045-015-0219-0.
Abstract
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting developments, there remains room for improvement in treatment outcomes. Combination immunotherapy, in particular combined cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) blockade, represents an important first step in this direction.
摘要
由于有效的全身治疗选择较少，晚期黑色素瘤在历史上一直是一种难以治疗的疾病。然而，在过去几年中，免疫检查点抑制方面的科学进展带来了几种新方法，改变了晚期黑色素瘤的一线治疗管理。尽管有这些令人兴奋的进展，但治疗结果仍有改善的空间。联合免疫疗法，特别是联合细胞毒性T淋巴细胞相关蛋白4（CTLA-4）和程序性死亡1（PD-1）阻断，是朝着这个方向迈出的重要第一步。
相似文献
1
Nivolumab plus ipilimumab in the treatment of advanced melanoma.
J Hematol Oncol. 2015 Oct 31;8:123. doi: 10.1186/s13045-015-0219-0.
2
Nivolumab: A Review in Advanced Melanoma.
Drugs. 2015 Aug;75(12):1413-24. doi: 10.1007/s40265-015-0442-6.
3
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
J Clin Oncol. 2017 Dec 1;35(34):3815-3822. doi: 10.1200/JCO.2016.72.1167. Epub 2017 Sep 15.
4
The role of nivolumab in melanoma.
Future Oncol. 2018 Jun;14(13):1241-1252. doi: 10.2217/fon-2017-0484. Epub 2018 Jan 12.
5
Nivolumab in melanoma.
Expert Rev Anticancer Ther. 2016 Dec;16(12):1247-1261. doi: 10.1080/14737140.2016.1249856. Epub 2016 Nov 7.
6
[Not Available].
Bull Cancer. 2016 Jun;103(6 Suppl 1):S4-S11. doi: 10.1016/S0007-4551(16)30140-0.
7
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.
8
Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma.
Expert Opin Biol Ther. 2016;16(3):389-96. doi: 10.1517/14712598.2016.1141195. Epub 2016 Feb 1.
9
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.
10
Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?
Clin Cancer Res. 2016 Aug 15;22(16):3992-8. doi: 10.1158/1078-0432.CCR-15-2944. Epub 2016 Jun 23.
引用本文的文献
1
Immunotherapy in melanoma: advances, pitfalls, and future perspectives.
Front Mol Biosci. 2024 Jun 28;11:1403021. doi: 10.3389/fmolb.2024.1403021. eCollection 2024.
2
Machine learning-based identification of glycosyltransferase-related mRNAs for improving outcomes and the anti-tumor therapeutic response of gliomas.
Front Pharmacol. 2023 Aug 16;14:1200795. doi: 10.3389/fphar.2023.1200795. eCollection 2023.
3
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Cell Commun Signal. 2022 Apr 7;20(1):44. doi: 10.1186/s12964-022-00854-y.
4
The Potential Predictors in Chemotherapy Sensitivity.
Adv Exp Med Biol. 2021;1187:381-389. doi: 10.1007/978-981-32-9620-6_19.
5
Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes.
Drug Des Devel Ther. 2018 Jul 4;12:2025-2038. doi: 10.2147/DDDT.S154258. eCollection 2018.
6
Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.
Melanoma Res. 2018 Jun;28(3):211-221. doi: 10.1097/CMR.0000000000000441.
7
The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.
Viruses. 2018 Mar 2;10(3):108. doi: 10.3390/v10030108.
8
Sarcoid-like reactions in patients receiving modern melanoma treatment.
Melanoma Res. 2018 Jun;28(3):230-236. doi: 10.1097/CMR.0000000000000437.
9
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.
J Hematol Oncol. 2017 Dec 1;10(1):174. doi: 10.1186/s13045-017-0541-9.
10
Current Development Status of MEK Inhibitors.
Molecules. 2017 Sep 26;22(10):1551. doi: 10.3390/molecules22101551.
本文引用的文献
1
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
2
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20.
3
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
J Immunol. 2015 Feb 1;194(3):950-9. doi: 10.4049/jimmunol.1401686. Epub 2014 Dec 24.
4
Nivolumab in previously untreated melanoma without BRAF mutation.
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
5
Strategies for modern biomarker and drug development in oncology.
J Hematol Oncol. 2014 Oct 3;7:70. doi: 10.1186/s13045-014-0070-8.
6
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
Nat Immunol. 2013 Dec;14(12):1212-8. doi: 10.1038/ni.2762.
7
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
8
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
N Engl J Med. 2011 Jun 30;364(26):2517-26. doi: 10.1056/NEJMoa1104621. Epub 2011 Jun 5.
9
Improved survival with ipilimumab in patients with metastatic melanoma.
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
10
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80. doi: 10.1073/pnas.0915174107. Epub 2010 Feb 16.
Zotero 插件